CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential

Syed Z.A. Zaidi; Ibraheem H. Motabi; Ali Al-Shanqeeti

首页> 外文期刊>Hematology/Oncology and Stem Cell Therapy >CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential

【24h】

CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential

机译：CD56和RUNX1亚型在AML预后中的治疗潜力

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Neural cell adhesion molecule (NCAM/CD56) expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia, multidrug resistance, shorter remission and survival. Recently, Bloomfield et al. published a succinct review of issues surrounding the AML prognostication and current therapeutics. However, we want to reiterate the prognostic value and therapeutic potential of CD56 that is frequently expressed in AML as was also reported by their own group earlier. In addition, novel RUNX1 isoforms contribute in controlling CD56 expression in AML cells. Anti-CD56 antibody therapy deserves exploration as an arsenal against AML patients expressing CD56. Relevantly, targeting RNA splicing machinery or RUNX1 isoform-specific siRNA may also become part of future therapeutic strategies for AML with CD56 overexpression.

机译：急性髓细胞性白血病（AML）中神经细胞粘附分子（NCAM / CD56）的表达与髓外白血病，多药耐药性，缓解期和生存期短有关。最近，Bloomfield等人。发表了有关AML预后和当前治疗方法的简要综述。但是，我们想重申CD56在AML中经常表达的预后价值和治疗潜力，正如他们自己的研究小组先前所报道的那样。此外，新型RUNX1亚型有助于控制AML细胞中的CD56表达。抗CD56抗体疗法作为针对表达CD56的AML患者的武器库值得探索。与此相关，靶向RNA剪接机制或RUNX1亚型特异性siRNA也可能成为CD56过表达的AML未来治疗策略的一部分。

著录项

来源
《Hematology/Oncology and Stem Cell Therapy》 |2016年第3期|共2页
作者
Syed Z.A. Zaidi; Ibraheem H. Motabi; Ali Al-Shanqeeti;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类一般性问题;
关键词

相似文献

外文文献
中文文献
专利

1. The Number of RUNX1 Mutations and the Presence of One Intact RUNX1 Allele Influence Cytogenetic Abnormalities, Additional Molecular Mutations and Prognosis in RUNX1 Mutated AML [J] . Stengel Anna, Kern Wolfgang, Meggendorfer Manja, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Runx1突变的数量和一个完整的runx1等位基因的存在会影响细胞遗传学异常，Runx1突变AML中的额外分子突变和预后
2. Expansion of functionally defined mouse hematopoietic stem and progenitor cells by a short isoform of RUNX1/AML1. [J] . Tsuzuki S, Seto M Blood: The Journal of the American Society of Hematology . 2012,第3期

机译：RUNX1 / AML1的短异构体可扩增功能定义的小鼠造血干细胞和祖细胞。
3. Isoform-Specific Potentiation of Stem and Progenitor Cell Engraftment by AML1/RUNX1 [J] . Shinobu Tsuzuki, Dengli Hong, Rajeev Gupta, PLoS Medicine . 2007,第5期

机译：AML1 / RUNX1的干细胞和祖细胞移植的异构体特异性增强。
4. Structural Confirmation of a Potential Cancer Therapeutic: Pyruvate Kinase Activator Restores Active Conformation to M2 Isoform [C] . Graham M. West, Dimitrios Anastasiou, Bruce D. Pascal, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2013

机译：潜在癌症治疗的结构确认：丙酮酸激酶活化剂恢复为M2同种型的主动构象
5. The role of Runx1 N-terminal splice isoforms in hematopoietic development [D] . Hedblom, Emmett E. 2010

机译：Runx1 N端剪接异构体在造血发育中的作用
6. NCAM(CD56) and RUNX1(AML1) Are Up-Regulated in Human Ischemic Cardiomyopathy and a Rat Model of Chronic Cardiac Ischemia [O] . Stefan Gattenlöhner, Christiane Waller, Georg Ertl, 2003

机译：NCAM（CD56）和RUNX1（AML1）在人类缺血性心肌病和慢性心肌缺血的大鼠模型中上调。
7. CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential [O] . Zaidi Syed Z.A., Motabi Ibraheem H., Al-Shanqeeti Ali 2016

机译：CD56和RUNX1亚型在AML预后中的治疗潜力

CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential

摘要

著录项

相似文献

相关主题

期刊订阅